chitosan has been researched along with Parkinsonian Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Essa, MM; Guillemin, GJ; Karthik, R; Manigandan, V; Manivasagam, T; Nataraj, J; Saravanan, R; Thenmozhi, AJ | 1 |
| Cantù, L; Carafa, M; Del Favero, E; Esposito, G; Gigli, S; Hanieh, PN; Marianecci, C; Pesce, M; Rinaldi, F; Sarnelli, G; Seguella, L | 1 |
2 other study(ies) available for chitosan and Parkinsonian Disorders
| Article | Year |
|---|---|
Low Molecular Weight Sulfated Chitosan: Neuroprotective Effect on Rotenone-Induced In Vitro Parkinson's Disease.
Topics: Antiparkinson Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Chitosan; DNA Fragmentation; Dose-Response Relationship, Drug; Humans; Membrane Potential, Mitochondrial; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Reactive Oxygen Species; Rotenone | 2019 |
inPentasomes: An innovative nose-to-brain pentamidine delivery blunts MPTP parkinsonism in mice.
Topics: Administration, Intranasal; Animals; Anti-Inflammatory Agents; Antiparkinson Agents; Brain; Chitosan; Dopamine; Drug Liberation; Liposomes; Male; Mice, Inbred C57BL; Nasal Mucosa; Parkinsonian Disorders; Pentamidine | 2019 |